T-cell membrane protein (TIRC7) and peptides derived therefrom

Details T-cell membrane protein (TIRC7) and peptides derived therefrom T-cell membrane protein (TIRC7) and peptides derived therefrom

2011-01-04

2011-01-04

Ouspenski, Ilia (Department: 1644)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

C514S012200

Reexamination Certificate

active

07863418

ABSTRACT:
Described are a T cell immune response cDNA 7 (TIRC7) encoding a T-cell transmembrane protein, peptides and polypeptides derived therefrom and antibodies recognizing such (poly)peptides. Peptides, polypeptides and antibodies capable of inhibiting T-cell stimulation through the T-cell membrane protein (TIRC7) are provided. Vectors comprising polynucelotides encoding such polypeptides and peptides, host cells transformed therewith, and their use in the production of such, peptides or polypeptides are also described.

REFERENCES:
patent: 5183657 (1993-02-01), Burrman
patent: 5747034 (1998-05-01), de Boer et al.
patent: 5827516 (1998-10-01), Urban et al.
patent: 6777537 (2004-08-01), Stashenko et al.
patent: 2003/0124614 (2003-07-01), Utku et al.
patent: 2005/0048067 (2005-03-01), Utku et al.
patent: 2006/0292143 (2006-12-01), Utku et al.
patent: WO 9423033 (1994-10-01), None
patent: WO 9803651 (1998-01-01), None
Attwood T., Science 2000; 290:471-473.
Skolnick et al., Trends in Biotech. 2000; 18(1):34-39.
Blazer et al., J. Immunol., 1996, 157: 3250-3259.
Sequence aligment, 2 pages, (2008).
Jeffrey A. Blueston and Jeffrey B. Matthews (2000), “Editorial”Clinical Immunology, vol. 96(3): 171-173.
Cohen, IR and Miller, A. “Autoimmune Disease Models”,Academic Press Limited, 1994 (preface).
Cramer, DV, Podesta, LG, and Makowka, L. “Handbook of Animal Models In Transplantation Research”CRC Press Inc. 1994 (p. 8).
Mohamed H. Sayegh, et al. (1995) “CD28-B7 Blockade After Alloantigenic Challenge In Vivo Inhibits Th1 Cytokines but Spares Th2”J. Exp. Med181: 1869-1874.
Kirk et al. (1997) “CTLA4-Ig and anti-CD40 Ligand Prevent Renal Allograft Rejection in Primates”,Proc. Natl. Acad. Sci. USA94:8789-8794.
Filmore, D (2004) “It's a GPOCR World”Modern Drug Discovery7(11): 24-28.
Pending Claims in U.S. Appl. No. 11/510,868, published as U.S. Patent Publication No. 2006/0292143 for Utku et al., (2006).
Dec. 12, 1998 International Search Report in connection with International Application No. PCT/EP98/05462.
Dec. 29, 1999 International Preliminary Examination Report in connection with International Application No. PCT/EP98/05462.
Aug. 11, 1999 Written Opinion in connection with International Application No. PCT/EP98/05462.
Nov. 10, 1999 Response to Aug. 11, 1999 Written Opinion in connection with International Application No. PCT/EP98/05462.
Nov. 25, 1999 Written Opinion in connection with International Application No. PCT/EP98/05462.
Dec. 10, 1999 Response to Nov. 25, 1999 Written Opinion in connection with International Application No. PCT/EP98/05462.
Mar. 5, 2002 European Patent Office Communication pursuant to Article 96(2) EPC in connection with European Application No. EP 98 945 293.
Jun. 27, 2002 Response to the Mar. 5, 2002 Communication pursuant to Article 96(2) EPC in connection with European Application No. EP 98 945 293.
Database Embl [Online] ID No. HS1196311, AC No. AA293678, Apr. 22, 1997 Hillier L et al:‘Homo sapienscDNA clone similar to specific 116-kDa vacuolar proton pump subunit’.
Database Embl [Online] AC No. A1088498, Aug. 19, 1998 NCI-CGAP:‘Homo SapienscDNA clone similar to specific 116-kDa vacuolar proton pump subunit’.
Heinemann, T. et al., “Genomic organization of the gene coding for TIRC7, a novel membrane protein essential for T cell activation”, May 1999, Genomics 57:398-406, XP000999606.
Nov. 6, 2000 Examiner's Report in connection with Australian Patent Application No. 92654/98.
Sep. 12, 2001 Response to Examiner's Nov. 6, 2000 Report filed in connection with Australian Patent Application No. 92654/98.
Sep. 21, 2001 Examiner's Report in connection with Australian Patent Application No. 92654/98.
Oct. 29, 2001 Response to Examiner's Sep. 21, 2001 Report filed in connection with Australian Patent Application No. 92654/98.
Nov. 9, 2001 Examiner's Report in connection with Australian Patent Application No. 92654/98.
Jun. 5, 2002 Response to Examiner's Nov. 9, 2001 Report in connection with Australian Patent Application No. 92654/98.
Amac, N. et al., “Identification of a New Human (H+)—ATPase Proton Pump Homology Differentially Expressed in Alloactivated Lymphocytes”, Abstract for the American Society of Nephrology 27thAnnual Meeting, Oct. 26-29, 1994, J. Am. Soc. Nephrology, Sep. 5 (3):740.
N. Utku Amac et al., “Characterization of a Novel Human Gene (C7) Associated with Early Lymphocyte Activation”, Abstract for the Fifteenth Annual Meeting of the American Society of Transplant Physicians, May 27-30, 1996, No. P-6, p. 174.
Utku, Nalan et al., “Identification of T Cell Immune Response cDNA (TIRC7) in Alloactivated Human Lymphocytes”, Fifth Basic Sciences Symposium of the Transplantation Society, Program & Poster Abstracts, Sep. 6-11, 1997.
Utku, N. et al., “Characterization of a Novel T Cell Immune Response cDNA (TIRC7) Associated with Early Lymphocyte Activation”, Fourth International Symposium on Clinical Immunology, Jun. 19-22, '97.
N. Utku, et al., “Identification of T-cell immune response cDNA (TIRC-7) in allocativated human lymphocytes”, Abstract, Congress of Molecular Medicine, Berlin May 3-5, 1997.
Utku, N. et al., “Characterization of a Novel T-Cell Immune Response cDNA (TIRC7) Associated with Early Lymphocyte Activation”, XIIIth Spring Meeting of the Deutsche Gasellschaft für Immunologie, Mar. 6-8, 1997, (Abstract).
Utku, N. et al., “Antibodies to a Novel T Cell Antigen, TIRC7, Block Selectively TYP 1 But Not TYP 2 T-Cell Activation and Prolongs Allograft Survival”, Abstract for the 17thAnnual Scientific Meeting, (1998).
Anan Chuntharapai and K. Jin Kim, “Generation of Monoclonal Antibodies to Chemokine Receptors”, Methods in Enzymology, vol. 288, (1997), pp. 15-27.
Kumamoto, Yusuke et al., “Monoclonal Antibody Specific for TIRC7 Induces Donor-specific Anergy and Prevents Rejection of Cardiac Allografts in Mice”, American Journal of Transplantation, (2004), vol. 4, pp. 505-514.
Utku, Nalan et al., “TIRC7 Deficiency Causes In Vitro and In Vivo Augmentation of T and B Cell Activation and Cytokine Response”, The Journal of Immunology, vol. 173, (2004), pp. 2342-2352.
Utku, Nalan et al., “Prevention of Acute Allograft Rejection by Antibody Targeting of TIRC7”, a Novel T Cell Membrane Protein, Immunity, vol. 9, (1998), pp. 509-518.
Yi-Ping Li et al., “Molecular cloning and characterization of a putative novel human osteoclast-specific 116-kDa vacuolar proton pump subunit”, Biochemical and Biophysical Research Communications, vol. 218, No. 3, (1996), pp. 813-821.
Chong-Kil Lee et al., “Cloning of a cDNA for a T cell produced molecule with a putative immune regulatory role”,Molecular Immunology, vol. 27, No. 11, (1990), pp. 1137-1144.
U.S. Appl. No. 11/126,841, Nalan Utku et al.
Sato S.B. and Toyama s. (1994) Inter.WithTheEndo.Acidif.ByAMonoclon.Antib.Direc.Towrd.The 116 (100) -kD Subunt.OfTheVacuo.TypePrtn.Pump,TheJ.OfCellBio.,V.127(1), pp. 39-53.
Claims pending in U.S. Appl. No. 10/489,725, (as of 2009).

Affiliated with

Also associated with

Rating

T-cell membrane protein (TIRC7) and peptides derived therefrom does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with T-cell membrane protein (TIRC7) and peptides derived therefrom, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and T-cell membrane protein (TIRC7) and peptides derived therefrom will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2703257